1. Home
  2. RNXT vs CGTX Comparison

RNXT vs CGTX Comparison

Compare RNXT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • CGTX
  • Stock Information
  • Founded
  • RNXT 2012
  • CGTX 2007
  • Country
  • RNXT United States
  • CGTX United States
  • Employees
  • RNXT N/A
  • CGTX N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RNXT Health Care
  • CGTX Health Care
  • Exchange
  • RNXT Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • RNXT 31.6M
  • CGTX 30.0M
  • IPO Year
  • RNXT 2021
  • CGTX 2021
  • Fundamental
  • Price
  • RNXT $1.42
  • CGTX $0.65
  • Analyst Decision
  • RNXT Strong Buy
  • CGTX Strong Buy
  • Analyst Count
  • RNXT 2
  • CGTX 6
  • Target Price
  • RNXT $6.50
  • CGTX $8.30
  • AVG Volume (30 Days)
  • RNXT 105.7K
  • CGTX 1.0M
  • Earning Date
  • RNXT 03-31-2025
  • CGTX 03-25-2025
  • Dividend Yield
  • RNXT N/A
  • CGTX N/A
  • EPS Growth
  • RNXT N/A
  • CGTX N/A
  • EPS
  • RNXT N/A
  • CGTX N/A
  • Revenue
  • RNXT N/A
  • CGTX N/A
  • Revenue This Year
  • RNXT N/A
  • CGTX N/A
  • Revenue Next Year
  • RNXT N/A
  • CGTX N/A
  • P/E Ratio
  • RNXT N/A
  • CGTX N/A
  • Revenue Growth
  • RNXT N/A
  • CGTX N/A
  • 52 Week Low
  • RNXT $0.77
  • CGTX $0.34
  • 52 Week High
  • RNXT $1.86
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 51.63
  • CGTX 45.88
  • Support Level
  • RNXT $1.31
  • CGTX $0.60
  • Resistance Level
  • RNXT $1.69
  • CGTX $0.82
  • Average True Range (ATR)
  • RNXT 0.11
  • CGTX 0.06
  • MACD
  • RNXT -0.01
  • CGTX -0.02
  • Stochastic Oscillator
  • RNXT 15.79
  • CGTX 27.63

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: